Full Press Release Details
Enters Research Agreement to Identify Novel Targets for Cancer Treatment
PA and VANCOUVER, British Columbia, June 29, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"
or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today
announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty
member. The project aims to discover new targets that may lead to the development of novel anti-cancer treatments.
research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy
and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers. The research team at Harvard Medical
School is led by Joan S. Brugge, PhD, who is the Louise Foote Pfeiffer Professor of Cell Biology and Co-Director of the Ludwig Cancer
are grateful for the opportunity to work with Prof. Brugge and her expert team at Harvard Medical School to advance discovery in oncology,"
stated Dr. Miguel Lopez-Lago, BriaCell's Chief Scientific Officer. "We are hopeful that insights from this effort may potentially
inform BriaCell's future R&D aims in developing novel anti-cancer drugs. This research collaboration is in line with our overall
strategy of developing safe and effective treatments for cancer patients with large unmet medical needs."
have made tremendous strides in understanding the basic biology of cancer over the last decade. Despite this formidable progress, persistent
challenges remain in translating these discoveries into effective and safe precision-targeted cancer treatments," stated Brugge.
"Our work aims to solve these challenges."
will have the option to negotiate a license to innovations owned by Harvard University that arise under the one-year collaboration. The
research agreement was coordinated by Harvard's Office of Technology Development.
BriaCell Therapeutics Corp.
is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information
is available at https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Examples of forward-looking statements in this news release include, among others, statements that the
Company makes regarding the potential for discovering and developing new targets that may lead to the development of novel anti-cancer
treatments. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks
and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk
Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's
other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available
under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this
announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required
under applicable law.
Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.